CURRICULUM VITAE

Ann C. Childress, M.D.

Personal Data:

Office Address: Center for Psychiatry and Behavioral Medicine, Inc 7351 Prairie Falcon Rd, Suites 150 & 160 Las Vegas, NV 89128

Office Telephone: 702-838-0742

Military Service: Lieutenant Colonel (sel) United States Air Force September 1992-September 1998 Honorable Discharge

Employment:

April 2004 – Present Psychiatrist and President Center for Psychiatry and Behavioral Medicine, Inc 7351 Prairie Falcon Rd, Suites 150 & 160 Las Vegas, NV 89128

June 2014 – Present Adjunct Associate Professor Touro University Nevada 874 American Pacific Drive Henderson, NV 89014

March 2003 –2018 Staff Psychiatrist Spring Mountain Treatment Center 7000 W. Spring Mountain Rd. Las Vegas, NV 89117

January 2012 – Present Courtesy Staff Psychiatrist July 2002 – July 2008 Montevista Hospital 5900 W. Rochelle Avenue Las Vegas, NV 89103

April 2001 - Present Adjunct Faculty University of Nevada School of Medicine Reno, NV

Jan 2019 – Present Clinical Associate Professor Dept. of Family Medicine University of Nevada Las Vegas School of Medicine Las Vegas, NV Page 2

Employment (cont.):

April 2001 –August 2004 Psychiatrist and Vice President Nevada Behavioral Health, Inc 2055 West Charleston Blvd, Suite B Las Vegas, NV 89102

October 1998 – 2008 Staff Psychiatrist - University Medical Center 800 W. Charleston Blvd Las Vegas, NV 89102

October 1998 - March 2001 Assistant Professor and Vice-Chairman University of Nevada School of Medicine Department of Psychiatry Las Vegas, NV

July 1996 - September 1998 Chief, Mental Health 99th Medical Group Nellis Air Force Base, NV

March 1996 - July 1996 Chief, Outpatient Mental Health 96th Medical Group Eglin Air Force Base, FL

January 1994 - July 1996 Chief, Mental Health Consultation and Liaison Residency Education Representative 96th Medical Group Eglin Air Force Base, FL

October 1992 - July 1996 Psychiatrist 96th Medical Group Eglin Air Force Base, FL

January 1993 - July 1996 Member, Consulting Board of Trustees Rivendell Psychiatric Hospital Ft. Walton Beach, FL

August 1991 - July 1992 Courtesy Staff Psychiatrist Coastal Carolina Hospital Conway, SC Page 3

Education and Professional Training:

July 1990 - June 1992 Fellowship, Child and Adolescent Psychiatry Medical University of South Carolina Charleston, SC

July 1988 - June 1990 Resident in Psychiatry Medical University of South Carolina

June 1988 Completed Internship in Psychiatry Medical University of South Carolina

June 1987 Doctor of Medicine (M.D.) Medical University of South Carolina

June 1985 Completed Basic Sciences St. Louis University School of Medicine St. Louis, MO

May 1983 Bachelor of Arts (B.A.) Washington University St. Louis, MO Majors: Chemistry, Biology

Board Certification and Licensure:

June 1988 South Carolina License #13976 (currently inactive)

February 1997 Nevada License #8091

January 1993 American Board of Psychiatry and Neurology (ABPN) Certificate #36745

October 1993 ABPN Child and Adolescent Psychiatry Certificate #3197

January 2000 –2004 Examiner for ABPN Adult Psychiatry Child & Adolescent Psychiatry

Professional Societies:

American Psychiatric Association (Fellow) American Academy of Child and Adolescent Psychiatry American Professional Society of ADHD and Related Disorders Nevada Psychiatric Association

Honors and Awards: Page 4

July 1992 Child Psychiatry Research Award Medical University of South Carolina

June 1991 Benjamin C. Riggs Award "Best Resident Paper 1990-1991" Department of Psychiatry Medical University of South Carolina

May 1987 Alpha Omega Alpha Medical University of South Carolina Charleston, South Carolina

August 1983 - May 1987 Health Professions Scholarship St. Louis University School of Medicine Medical University of South Carolina

May 1983 Phi Beta Kappa Cum Laude R.O.T.C. Distinguished Graduate Washington University

August 1979 - May 1983 R.O.T.C. Scholarship Washington University

Publications:

Childress AC, Komolova M, Sallee RF. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting and formulations. Expert Opin Drug Metab Toxicol. 2019. [Epub ahead of print.]

Childress AC, Chow H. Amphetamine extended-release oral suspension for attention- deficit/hyperactivity disorder. Expert Rev Clin Pharmacol. 2019;12:965-971.

Childress AC, Cutler AJ, Marraffino A, McDonnell MA, Turnbow JM, Brams M, DeSousa NJ, Incledon B, Sallee FR, Wigal SB. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings. J Child Adolesc Psychopharmacol. 2019. [Epub ahead of print.]

Childress AC, Kando JC, King TR, Pardo A, Herman BK. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2019;29:2-8.

Publications (cont.):

Page 5

Childress AC, Newcorn JH, Cutler AJ. Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder. Adv Ther. 2019;36:1370-1387.

Wigal SB, Hopkins SC, Koblan KS, Childress A, Kent JM, Tsai J, Hsu J, Loebel A, Goldman R. Efficacy and Safety of in Children With ADHD: A Laboratory Classroom Study. J Atten Disord. 2019:1087054719864644.

Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, Newcorn JH. Practitioner Review: Emotional Dysregulation in Attention-Deficit/Hyperactivity Disorder - Implications for Clinical Recognition and Intervention. J Child Psychol Psychiatry. 2019;60:133-150.

Engelking D, Childress AC, McMahen R, Sikes CR. How to Dose Attention- Deficit/Hyperactivity Disorder Without a Grain of Salt. J Child Adolesc Psychopharmacol. 2018;28:576-577.

Abbas R, Childress AC, Nagraj P, Rolke R, Berry SA, Palumbo DR. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. Clin Ther. 2018;40:733-740.

Wigal SB, Childress A, Berry SA, Belden HW, Chappell P, Wajsbrot DB, Nagraj P, Abbas R, Palumbo D. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2018;28:314-321.

Childress AC, Wigal SB, Brams MN, Turnbow JM, Pincus Y, Belden HW, Berry SA. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018;28:306-313.

Childress AC, Stark JG. Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Preschool-Aged Children. J Child Adolesc Psychopharmacol. 2018;28:606-614.

Childress A, Ponce De Leon B, Owens M. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above. Expert Opin Drug Deliv. 2018;15:1263-1270.

Weiss M, Childress A, Nordbrock E, Adjei AL, Kupper RJ, Mattingly G. Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. J Clin Med. 2019;8. Page 6

Publications (cont.):

Wigal T, Childress A, Frick G, Yan B, Wigal S, Madhoo M. Effects of SHP465 Mixed Amphetamine Salts in Adults with ADHD in a Simulated Adult Workplace Environment. Postgrad Med. 2018 Jan;130(1):111-121.

Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):10-18.

Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of and Extended- Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017 Nov;31(11):999-1014.

Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo- Controlled Study. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):19-28.

Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699.

Childress A, Stark JG, McMahen R, Engelking D, Sikes C. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults. Clin Pharmacol Drug Dev. 2018 Feb;7(2):151-159.

Childress A. The Safety of Extended-Release Drug Formulations for the Treatment of ADHD. Expert Opin Drug Saf. 2017 May;16(5):603-615.

Childress A, Belchenko D, Lempa B. The Use of Modified-Release Methylphenidate in the Treatment of Attention-Deficit/Hyperactivity Disorder. Expert Rev Neurother. 2017 Feb;17(2):113-121.

Wigal SB, Wigal T, Childress A, Donnelly GAE, Reiz JL. The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. J Atten Disord. 2016 Oct 1. [Epub ahead of print]

Publications (cont.): Page 7

Owens J, Weiss M, Nordbrock E, Mattingly G, Wigal S, Greenhill LL, Chang WW, Childress A, Kupper RJ, Adjei A. Effect of Aptensio XR (Methylphenidate HCl Extended- Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2016 Dec;26(10):873-881.

Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):66-74.

Childress AC. Methylphenidate HCL for the Treatment of ADHD in Children and Adolescents. Expert Opin Pharmacother. 2016 Jun;17(8):1171-8.

Childress A, Tran C. (2016) Current Investigational Drugs for the Treatment of Attention Deficit Hyperactivity Disorder. Expert Opin Investig Drugs, 25(4):463-474.

Childress AC. (2015) A Critical Appraisal of in the Management of ADHD. Ther Clin Risk Manag, 12:27-39.

Faraone SV, Childress A, Wigal SB, Kollins SH, McDonnell MA, DeSousa NJ, Sallee FR. (2015) Reliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised. J Atten Disord. [Epub ahead of print]

Childress AC, Sallee FR. (2015) Emotional Lability in Patients with Attention- Deficit/Hyperactivity Disorder: Impact of Pharmacotherapy. CNS Drugs, 29(8):683-93.

Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L. (2015) Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. CNS Drugs, 29(4):331-40.

Childress AC, Brams M, Cutler AJ, Kollins SH, Northcutt J, Padilla A, Turnbow JM. (2015) The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose- Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. J Child Adolesc Psychopharmacol, 25(5):402-14.

Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, Childress A, Stehli A, Kupper RJ. (2014) A Randomized Placebo-Controlled Double-Blind Study Evaluating the Time Course of Response to Methylphenidate Hydrochloride Extended-Release Capsules in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 24(10):562-9.

Publications (cont.):

Page 8

Adjei A1, Kupper RJ, Teuscher NS, Wigal S, Sallee F, Childress A, Kollins SH, Greenhill L. (2014) Steady-State Bioavailability of Extended-Release Methylphenidate (MPH- MLR) Capsule vs. Immediate-Release Methylphenidate Tablets in Healthy Adult Volunteers. Clinical Drug Investigation, 34(11):795-805.

Childress AC, Sallee FR. (2014) for the Treatment of Attention- Deficit/Hyperactivity Disorder. Expert Opinion on Investigational Drugs, 23(11):1585-93.

Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB. (2014) Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD. Journal of Attention Disorders, pii: 1087054714533191.

Childress AC, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Findling RL. (2014) Participant-Perceived Quality of Life in a Long-Term, Open-Label Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 24(4):210-7.

Weisler RH, Adler LA, Kollins SH, Goodman DW, Hamdani M, Dirks B, Childress AC. (2014) Analysis of Individual Items on the Attention-Deficit/Hyperactivity Disorder Symptom Rating Scale in Children and Adults: The Effects of Age and Sex in Pivotal Trials of Lisdexamfetamine Dimesylate. Neuropsychiatric Disease and Treatment, 10:1-12.

Childress AC, Sallee FR. (2014) Attention-Deficit/Hyperactivity Disorder with Inadequate Response to : Approaches to Management. CNS Drugs, 28(2):121-9.

Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, Lasser R, Lopez FA. (2014) The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age with ADHD in a Double-Blind Placebo-Controlled Trial. Journal of Attention Disorders, 18(2):123-32.

Childress A, Sallee FR. (2013) The Use of Methylphenidate Hydrochloride Extended-Release Oral Suspension for the Treatment of ADHD. Expert Review of Neurotherapeutics, 13(9):979-88.

Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J. (2013) Randomized, Double-Blind Trial of Guanfacine Extended Release in Children with Attention-Deficit/Hyperactivity Disorder: Morning or Evening Administration. Journal of the American Academy of Child and Adolescent Psychiatry, 52(9):921- 30.

Publications (cont.):

Page 9

Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC. (2013) A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 23(1):11-21.

López FA, Childress A, Adeyi B, Dirks B, Babcock T, Scheckner B, Lasser R, Shepski J, Arnold V. (2013) ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years. J Atten Disord. 2017;21:52-61.

Wigal SB, Childress AC, Belden HW, Berry SA. (2013) NWP06, an Extended-Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared with Placebo in a Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology, 23(1):3-10.

Brams M, Turnbow J, Pestreich L, Giblin J, Childress A, McCague K, Muniz R. (2012) A Randomized, Double-Blind Study of 30 versus 20 mg Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder: Late- Day Symptom Control. Journal of Clinical Psychopharmacology, 32(5):637-44.

Childress AC. (2012) Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Advances in Therapy, 29(5):385-400.

Childress AC, Sallee FR. (2012) Revisiting Clonidine: An Innovative Add-On Option for Attention Deficit/Hyperactivity Disorder. Drugs Today (Barc), 48(3):207-217.

Childress AC, Berry SA. (2012) Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Adolescents. Drugs 72(3):309-325.

Childress AC, Sallee FR. (2012) The Use of Lisdexamfetamine Dimesylate for the Treatment of ADHD. Expert Rev Neurother 12(1):13-26.

Wilens TE, Bukstein O, Brams M, Cutler A, Childress A, Rugino T, Lyne A, Grannis K, Youcha S. (2012) A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 51(1):74-85.

Weisler RH, Childress AC. (2011) Treating Attention-Deficit/Hyperactivity Disorder in Adults: Focus on Once-Daily Medications. Prim Care Companion CNS Disord 13(6):e1-10.

Childress AC, Sallee FR, Berry SA. (2011) Single-Dose Pharmacokinetics of NWP06, an Extended-Release Methylphenidate Suspension, in Children and Adolescents with ADHD. Postgrad Med, 123(5):80-88.

Publications (cont.):

Page 10

López FA, Scheckner B, Childress AC. (2011) Physician Perception of Clinical Improvement in Children with Attention-Deficit/Hyperactivity Disorder: A Post Hoc Comparison of Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended Release in a Crossover Analog Classroom Study. Neuropsychiatr Dis Treat, 7:267-273.

Murray DW, Childress A, Giblin J, Williamson D, Armstrong R, Starr HL. (2010) Effects of OROS Methylphenidate on Academic, Behavioral, and Cognitive Tasks in Children 9 to 12 Years of Age with Attention-Deficit/Hyperactivity Disorder. Clin Pedi (Phila), 50(4):308-320.

Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L. (2011) Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 50(4):395-405.

Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, Olsen E, Robieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD. (2011) Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. J Am Acad Child Adolesc Psychiatry, 50(1):73-84.

Manos MJ, Brams M, Childress AC, Findling RL, López FA, Jensen PS. (2011) Changes in Emotions Related to Used to Treat ADHD. Part I: Literature Review Journal of Attention Disorders, 15(2):101-112.

Findling RL, Brams M, Childress AC, López FA, Manos MJ, Jensen PS. (2011) Changes in Emotions Related to Medication Used to Treat ADHD. Part II: Clinical Approaches. Journal of Attention Disorders, 15(2):113-121.

Weiss MD, Childress AC, Pucci ML, Hechtman L. (2010) Review of Long-Acting and Nonstimulant ADHD Pharmacotherapy in Canada. J Can Acad Child Adolesc Psychiatry, 19(4):s1-20.

Wigal SB, Kollins SH, Childress AC, Adeyi B. (2010) Efficacy and Tolerability of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder: Sex and Age Effects and Effect Size Across the Day. Child and Adolescent Psychiatry and Mental Health, 4:32.

Childress AC, Berry SA. (2010) The Single-Dose Pharmacokinetics of NWP06, a Novel Extended- Release Methylphenidate Oral Suspension. Postgrad Med, 122(5):35-41.

Publications (cont.):

Brown TE, Brams M, Gao J, Gasior M, Childress A. (2010) Open-Label Administration of Lisdexamfetamine Dimesylate Improves Executive Function Impairments and Page 11

Symptoms of Attention-Deficit/Hyperactivity Disorder in Adults. Postgrad Med, 122(5):7-17.

Childress, A. (2010). ADHD Clinical Trials. In M. Hertzman & L. Adler (Ed.), Clinical Trials in Psychopharmacology: A Better Brain, 2nd ed. (pp. 251-272). West Sussex, UK: Wiley-Blackwell.

Childress AC, Spencer T, Lopez F, Gerstner O, Thulasiraman A, Muniz R, Post A. (2009) Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules Administered Once Daily to Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol,19(4): 351-361.

Wigal SB, Kollins SH, Childress AC, Squires L; 311 Study Group. (2009) A 13-Hour Laboratory School Study of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. Child Adolesc Psychiatry Ment Health, 3(1):17.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez F & Silva R. (2008) A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder. CNS Drugs, 22(8):693-704.

Findling RL, Childress AC, Krishnan S & McGough JJ. (2008) Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention- Deficit/Hyperactivity Disorder. CNS Spectrums, 13(7):614-620.

Wilens TE, Boellner SW, Lopez FA, Turnbow JM, Wigal SB, Childress AC, Abikoff HB & Manos MJ. (2008) Varying the Wear Time of the Methylphenidate Transdermal System in Children with Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 47(6):700-708.

Silva R, Muniz R, McCague K, Childress A, Brams M & Mao A. (2008) Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Mullticenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and d,l-Methylphenidate and Placebo in a Laboratory Classroom Setting. Psychopharmacol Bull, 41(1):19-33.

Silva RR, Muniz R, Pestreich L, Brams M, Mao AR, Childress A & Wang J. (2008) Dexmethylphenidate Extended-Release Capsules in Children with Attention- Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry, 47(2):199-208.

Publications (cont.):

Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S & Zhang Y. (2007) Page 12

Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. Biol Psychiatry, 62(9):970-976.

Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA & Wang J. (2006) Efficacy and Duration of Effect of Extended-Release Dexmethylphenidate versus Placebo in Schoolchildren with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol, 16(3):239-251.

Silva, R., Muniz R., Pestreich LK., Brams M., Childress A., & Lopez FA., (2005). The Efficacy of Two Long-Acting Methylphenidate Formulas in Children with Attention- Deficit/Hyperactivity Disorder in a Laboratory Classroom Setting. J Child Adolesc Psychopharmacol, 15(4): 637-654.

Wagner, K.D., Ambrosini, P., Rynn, M., Wohlberg, C., Yang, R., Greenbaum, M.S., Childress, A., Donnelly, C., & Deas, D.; for the pediatric depression study group (2003). Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder: Two Randomized Controlled Trials. JAMA, 290(8):1033-1041.

Childress, A.C., Brewerton, T.D., Hodges, EL., & Jarrell, M.P. (1993). The Kids' Eating Disorders Survey (KEDS): A Study of Middle School Students. J Am Acad Child Adolesc Psychiatry 32:843-850.

Childress, A.C., Jarrell, M.P., & Brewerton, T.D. (1993). The Kids' Eating Disorders Survey (KEDS): Internal Consistency, Component Analysis, and Test-Retest Reliability. Eating Disorders: The Journal of Treatment and Prevention, 1:123-133.

Research (Grants):

U.S. Food and Drug Administration Center of Drug Evaluation Research - Office of Generic Drugs “Pharmacokinetic/Pharmacodynamic (PK/PD) Studies of Methylphenidate Extended Release Products in Attention Deficit Hyperactivity Disorder (ADHD) Patients” May 2014 – Present

Medical University Small Grants Program for Resident Research "Prevalence of Eating Disorders in Middle School Students" January 1991-December 1991

Speaker’s Bureau:

Shire Pharmaceutical Development, Inc.

Page 13

Tris Pharma, Inc.

Neos Therapeutics, Inc.

Pharmaceutical Research:

Pfizer, Inc. A Multi-Center 10-Week Randomized, Double-Blind, Co-Principal Investigator Placebo-Controlled, Flexible Dose Outpatient Study Of Sertraline in Children and Adolescents with Major Depressive Disorder April 2000- March 2001

Pfizer, Inc. A Multi-Center 24-Week, Open Label Extension Co-Principal Investigator Study of Sertraline in Children and Adolescents Previously Diagnosed with Major Depressive Disorder April 2000- October 2001

Janssen Research Foundation The Efficacy and Safety of Risperidone in the Co-Principal Investigator Treatment of Children and Adolescents with Schizophrenia January 2001- May 2006

Janssen Research Foundation The Efficacy and Safety of Risperidone in the Co-Principal Investigator Treatment of Children and Adolescents with Schizophrenia: A Follow-up Trial January 2001- May 2006

Shire Pharmaceutical Development, Inc. An Open-Label, Multi-Center Study to Assess Co-Principal Investigator Tolerability, Effectiveness and Quality of Life Associated with the Use of SLI-381 ( XR) In Children with Attention Deficit Hyperactivity Disorder (ADHD) in a Community Practice Setting April 2001- December 2001

Celltech Americas, Inc. A Randomized, Double-Blind Comparison of the Time Co-Principal Investigator Course of Response to Two Extended Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disorder in an Analog Classroom Setting April 2002 - August 2002 Page 14

Pharmaceutical Research (cont.):

Eli Lilly and Company Olanzapine Versus Placebo in the Treatment of Co-Principal Investigator Adolescents with Schizophrenia November 2002 – October 2004

Eli Lilly and Company Olanzapine Versus Placebo in the Treatment of Mania in Co-Principal Investigator Adolescents with Bipolar I Disorder November 2002 – October 2004

AstraZeneca Pharmaceuticals Efficacy and Tolerability of Olanzapine, and Co-Principal Investigator Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison January 2003 – November 2004

Eli Lilly and Company Maintenance and Benefit after 8-Week and 52-Week Sub- Principal Investigator Treatment with Atomoxetine Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity Disorder January 2003 – January 2006

Novartis Pharmaceutical Corp. A Multicenter, Double-Blind, Placebo Controlled Trial to Principal Investigator Evaluate the Efficacy, Safety and Tolerability of Trileptal (oxcarbazepine) in the Treatment of Children and Adolescents with Bipolar Disorder Type I May 2003 – May 2004

Novartis Pharmaceutical Corp. A Randomized, Multi-Center, Single-Blind, Placebo- Co-Principal Investigator Controlled Cross-Over Study Comparing the Efficacy of Ritalin LA versus Concerta in Children with Attention- Deficit/Hyperactivity Disorder (ADHD) in an Analog Classroom Setting May 2003 - November 2003

Shire Pharmaceutical Development, Inc. A Randomized, Double-Blind, Parallel-Group, Analog Principal Investigator Classroom Study, Evaluating ADDERALL XR vs. SRATERRA, Dosed Once-Daily, in Children aged 6 – 12 with Attention-Deficit/ Hyperactivity Disorder (ADHD) July 2003 – March 2004

Eli Lilly and Company Open-Label Treatment with Atomoxetine Hydrochloride Principal Investigator in Children and Adolescents with Attention- Deficit/Hyperactivity Disorder and Comorbid Dyslexia July 2003 – January 2006

Pharmaceutical Research (cont.):

Page 15

Pfizer, Inc. A 27-Week Open-Label Trial to Characterize the Safety A1281123 and Tolerability of Orally Administered in Principal Investigator Children and Adolescent Subjects with Bipolar I Disorder (Manic or Mixed), Schizophrenia or Schizoaffective Disorder December 2003 – March 2005

Novartis Pharmaceutical Corp A Randomized, Multi-Center, Double-Blind, Cross-Over Principal Investigator Study Comparing the Efficacy and Duration of Focalin LA 20 mg versus Placebo in Children (6-12 Years) with Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting March 2004 – May 2004

Shire Pharmaceutical Development, Inc. A Phase 2, Randomized, Double-blind, Multi-Center, Principal Investigator Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) April 2004 - October 2004

Pfizer, Inc. A Randomized, Double-Blind, Placebo-Controlled Principal Investigator Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder May 2004 – December 2005

Pfizer, Inc. An Open-Label Study to Assess the Safety and Principal Investigator Tolerability of Xanax XR in the Treatment of Adolescents with Panic Disorder or with Panic Attacks May 2004 – December 2005

Pfizer, Inc. A Randomized, Double-blind, Placebo-Controlled Study Principal Investigator of Continuation Treatment with Xanax XR in the Treatment of Adolescents with a Primary Diagnosis of Panic Disorder May 2004 – December 2005

Shire Pharmaceutical Development, Inc. A Phase II, Randomized, Double-blind, Multi-Center, Sub- Principal Investigator Placebo- and Active-Controlled, Crossover Study of SPD465 in Adolescents with Attention-Deficit/ Hyperactivity Disorder (ADHD) October 2004 – February 2005

Pharmaceutical Research (cont.):

Page 16

New River Pharmaceuticals A Phase 2, Randomized, Double-Blind, Placebo- and Principal Investigator Active- Controlled, 3-Treatment, 3-Period, Crossover Study with One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR or Placebo in Children Aged 6 to 12 Years with Attention-Deficit/ Hyperactivity Disorder (ADHD) October 2004 – February 2005

New River Pharmaceuticals A Phase 3, Randomized, Multi-Center, Double-Blind, Principal Investigator Parallel-Group, Placebo- Controlled Study of NRP104 in Children Aged 6 to 12 Years with Attention-Deficit/ Hyperactivity Disorder (ADHD) October 2004 – January 2006

New River Pharmaceuticals A Long-Term, Open-Label, and Single-Arm Study of Principal Investigator NRP104 30 mg, 50 mg, or 70 mg Per Day in Children Aged 6 to 12 Years with Attention-Deficit/ Hyperactivity Disorder (ADHD) October 2004 – March 2006

Novartis Pharmaceutical Corp A Randomized, Multi-Center, Double-Blind, Cross-Over Principal Investigator Study Comparing the Efficacy and Safety of Focalin XR 20 mg versus Placebo in Children (6-12 years) with Attention- Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting October 2004 – February 2005

AstraZeneca A 6-week, International, Multi-Center, Randomized, Principal Investigator Double-Blind, Parallel-Group, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Daily Doses of 400 mg and 800 mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia October 2004 – May 2007

Pfizer, Inc. A Multicenter, 10-Week, Randomized, Double-Blind Principal Investigator Study of Sertraline and Placebo in Children and Adolescents with Posttraumatic Stress Disorder (PTSD) October 2004 – August 2007

Pharmaceutical Research (cont.):

AstraZeneca A 3-week, Multi-center, Randomized, Principal Investigator Double-Blind, Parallel-Group, Placebo-Controlled, Phase Page 17

IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania October 2004 – September 2006

AstraZeneca A 26-week, International, Multi-Center, Open-Label, Principal Investigator Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Daily Doses of 400 mg and 800 mg in the Treatment of Children and Adolescents with Bipolar I Mania and Adolescents with Schizophrenia October 2004 – September 2006

AstraZeneca A Multicenter, Open-Label, Flexible-Dose, Parallel- Principal Investigator Group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL) and Risperidone (RISPERDAL) in the Long-Term Treatment of Patients with Schizophrenia or Schizoaffective Disorder October 2004 – August 2008

Shire Pharmaceutical Development, Inc. A Phase III, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Parallel Group, Safety and Efficacy Study of SPD465 in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) November 2004 – January 2005

Otsuka Maryland Research Institute, Inc. A Multicenter, Randomized, Double-Blind, Placebo- Principal Investigator Controlled Study of Two Fixed Oral Dose of Aripiprazole (10 mg or 30 mg) in the Treatment of Adolescent Patients with Schizophrenia January 2005 – October2006

Otsuka Maryland Research Institute, Inc. A Multicenter, Randomized, Double-Blind, Placebo- Principal Investigator Controlled Study of Two Fixed Oral Dose of Aripiprazole (10 mg or 30 mg) in the Treatment of Child and Adolescent Patients Ages 10 – 17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features January 2005 – December 2006

Pharmaceutical Research (cont.):

Otsuka Maryland Research Institute, Inc. A Multicenter, Open-Label, Safety and Tolerability Study Principal Investigator of Flexible-Dose Oral Aripiprazole (2 mg - 30 mg) in the Treatment of Adolescent Patients Page 18

with Schizophrenia and Child and Adolescent Patients with Bipolar I Disorder, Manic of Mixed Episode with or without Psychotic Features January 2005 – December 2006

Shire Pharmaceutical Development, Inc. A Phase III, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of SPD465 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) April 2005 – November 2005

Shire Pharmaceutical Development, Inc. A Phase III, Multi-Center, 12-month, Open-Label Safety Principal Investigator Study of SPD465 in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) April 2005- December 2006

Novartis Pharmaceutical Corp A Randomized, Multi-Center, Double-Blind, Cross-Over Principal Investigator Study Comparing the Efficacy and Safety of Focalin XR (20 mg and 30 mg) versus Concerta (36 mg and 54 mg) and Placebo in Children (6-12 Years) with Attention- Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting April 2005 – November 2005

Shire Pharmaceutical Development, Inc. A Phase IIIB, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Dose-Optimization, 3-Way Cross- Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects aged 6 – 12 with Attention-Deficit/Hyperactivity Disorder June 2005 – March 2006

Shire Pharmaceutical Development, Inc. A Phase II, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Crossover Study of SPD465 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) August 2005 – March 2006

Pharmaceutical Research (cont.):

Novartis Pharmaceuticals Corp A 5-Week Treatment, Multi-Center, Double-Blind, Principal Investigator Randomized, Placebo-Controlled, Parallel-Group, Fixed- Dose Study of the Efficacy, Tolerability and Safety of Dexmethylphenidate HC1 Extended-Release Capsules Page 19

(Focalin XR) Administered Once Daily in Pediatric Patients 6-12 Years of Age with Attention- Deficit/Hyperactivity Disorder January 2006 – January 2007

Pfizer, Inc. Multicenter, Randomized, Double-Blind, Placebo- Principal Investigator Controlled Study of the Efficacy and Tolerability of Indiplon Therapy Initiated with Sertraline versus Sertraline Monotherapy in Subjects with and Co-Existing Major Depressive Disorder April 2006 – January 2007

Sanofi-Aventis Efficacy, Safety and Tolerability of Zolpidem in the Principal Investigator Treatment of Children Aged 6 – 17 Years with ADHD- Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study April 2006 – September 2006

New River Pharmaceuticals A Phase III, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) April 2006 – January 2007

New River Pharmaceuticals A Long-Term, Open-Label, and Single-Arm Study of Principal Investigator NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) April 2006 – February 2008

Bristol-Meyers Squibb Pharmaceuticals A Multicenter Double-Blind, Randomized, Placebo- Principal Investigator Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder April 2006 – July 2008

Bristol-Meyers Squibb Pharmaceuticals A 52-Week, Open-Label, Multicenter Study of the Safety Principal Investigator and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder April 2006 – June 2009

Pharmaceutical Research (cont.):

Novartis Pharmaceuticals Corporation An Open-Label, Behavioral-Treatment-Controlled Principal Investigator Evaluation of the Effects of Extended Release Methylphenidate (Ritalin LA) on the Frequency of Cytogenetic Abnormalities in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder (ADHD) Page 20

November 2006 – September 2008

Novartis Pharmaceuticals Corporation An 8-Week, Randomized, Double-Blind, Fixed-Dosage, Principal Investigator Placebo-Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-Week, Open-Label Extension November 2006 – January 2009

Shire Pharmaceutical Development, Inc A Phase IV, Multi-Center, Open-Label Study of Daytrana Principal Investigator (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) January 2007 – November 2007

Johnson and Johnson Pharmaceutical A 6-Month, Open-Label, Single-Arm Safety Study of Research and Development Flexibly Dosed Paliperidone Extended Release (1.5-12 Principal Investigator 2mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia May 2007 – December 2010

Somerset Pharmaceuticals, Inc. A Phase IV, Double-Blind, Placebo-Controlled, Principal Investigator Randomized, Flexible-Dose Study of the Safety and Efficacy of EMSAM® in Adolescents with Major Depression June 2007 – December 2009

Shire Pharmaceuticals Corporation A Phase IIIb, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of Vyvanse in Pediatric Subjects 6-12 with Attention- Deficit/Hyperactivity Disorder June 2007 – March 2008

Pharmaceutical Research (cont.):

Abbott Laboratories A Randomized, Double-Blind, Placebo-Controlled, Principal Investigator Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children with Attention- Deficit/Hyperactivity Disorder (ADHD) August 2007 – May 2008

Page 21

AstraZeneca Research and Development A Multi-Center Randomized, Placebo-Controlled, Principal Investigator Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of AZD3480 During 12 Weeks Treatment of Cognitive Defects in Patients with Schizophrenia September 2007 – June 2008

Novartis Pharmaceuticals Corporation A Randomized, Multi-Center, Double-Blind, Cross-Over Principal Investigator Study Comparing the Efficacy and Safety of Focalin® XR 20 mg versus Placebo at the 0.5 Hour Timepoint (Post- Dose) in Children (6-12 Years) with Attention- Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting October 2007 – January 2008

Eli Lilly and Company A Double-Blind Study of Atomoxetine Hydrochloride Principal Investigator vs Placebo for the Treatment of ADHD in Young Adults with an Assessment of Associated Functional Outcomes October 2007 – December 2009

Abbott Laboratories The Long-Term Safety and Tolerability of ABT-089 in Principal Investigator Children with Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study November 2007 – October 2008

Neuropharm Ltd Study of in Autism: A Randomized, Double- Principal Investigator Blind, Placebo-Controlled, Parallel-Group, 14-Week Study to Investigate the Effect of Fluoxetine Orally Dissolving Tablet (ODT) on Repetitive Behaviors in Childhood and Adolescent Autistic Spectrum Disorder December 2007 – March 2009

Bristol-Meyers Squibb Pharmaceuticals A Multicenter, Double-Blind, Randomized, Placebo- Principal Investigator Controlled, Parallel-Group Study with Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents with Autistic Disorder February 2008 – June 2008

Pharmaceutical Research (cont.):

Abbott Laboratories A Randomized, Double-Blind, Placebo-Controlled, Principal Investigator Parallel-Group, Phase 2 Study of the Safety and Efficacy of 0.7 mg/kg/day and 1.4 mg/kg/day of ABT-089 in the Treatment of Children with Attention- Deficit/Hyperactivity Disorder (ADHD) March 2008 – October 2008

Page 22

Shire Pharmaceutical Development, Inc. A Phase IIIb Randomized, Double-Blind, Multicenter, Principal Investigator Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) July 2008 – February 2009

Novartis Pharmaceuticals Corp. A Randomized, Multi-Center, Double-Blind, Placebo- Principal Investigator Controlled, Cross-Over Study Evaluating the Safety and Efficacy of Focalin XR 30 mg vs Focalin XR 20 mg as Measured by SKAMP-Combined Scores in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting September 2008 – January 2009

Shire Pharmaceutical Development, Inc A Phase III, Double-Blind, Randomized, Placebo- Principal Investigator Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents Aged 6-17 Years with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) September 2008 – February 2010

Shire Pharmaceutical Development, Inc A Phase III, Randomized, Double-Blind, Multi-Center, Principal Investigator Parallel-Group, Placebo-Controlled, Force-Dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents 13-17 with Attention- Deficit/Hyperactivity Disorder (ADHD) October 2008 – June 2009

Shire Pharmaceutical Development, Inc A Phase III, Open-Label, Extension, Multi-center, Safety Principal Investigator and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 with Attention- Deficit/Hyperactivity Disorder (ADHD) October 2008 – June 2010

Pharmaceutical Research (cont.):

Ortho-McNeil Janssen Scientific Double-Blind, Randomized, Placebo-Controlled, Affairs, L.L.C. Crossover Study Evaluating the Academic, Behavioral Principal Investigator and Cognitive Effects of CONCERTA on Older Children with ADHD (The ABC Study) November 2008 – August 2009

NextWave Pharmaceuticals, Inc. NWP06 in the Treatment of Children with ADHD: Principal Investigator A Laboratory Classroom Study Page 23

April 2009 – August 2009

Shire Pharmaceutical Development, Inc A Phase 4, Double-Blind, Multi-Center, Placebo- Principal Investigator Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 with Attention-Deficit/Hyperactivity Disorder (ADHD) April 2009 – October 2010

Sepracor Inc. A Randomized, Placebo-Controlled, Double-Blind, Principal Investigator Fixed-Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) with Attention-Deficit/Hyperactivity Disorder-Associated Insomnia May 2009 – October 2011

Sepracor Inc. A Long-Term, Open-Label, Safety Study of Principal Investigator Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) with Attention- Deficit/Hyperactivity Disorder-Associated Insomnia May 2009 – December 2011

Eli Lilly and Company A Fixed-Dose, Randomized, Double-Blind, Placebo- Principal Investigator Controlled Study of LY2216684 in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder July 2009 – February 2011

Eli Lilly and Company Long-Term, Open-Label, Safety Study of LY2216684 in Principal Investigator Pediatric Patients with Attention- Deficit/Hyperactivity Disorder October 2009 – October 2015

Ortho-McNeil Janssen Scientific A Placebo-Controlled, Double-Blind, Parallel-Group, Affairs, L.L.C. Individualized Dosing Study Optimizing Treatment of Principal Investigator Adults with Attention- Deficit/ Hyperactivity Disorder to an Effective Response with OROS Methylphenidate October 2009 – June 2010 Pharmaceutical Research (cont.):

Shire Pharmaceutical Development, Inc A Phase 3, Double-Blind, Randomized, Multicenter, Principal Investigator Placebo-Controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing with Extended-Release Guanfacine Hydrochloride in Children Aged 6-12 with a Diagnosis of Attention- Deficit/Hyperactivity Disorder November 2009 – October 2010

NextWave Pharmaceuticals, Inc. Evaluation of the Single Dose Pharmacokinetics of Principal Investigator NWP06 in Children and Adolescents with ADHD Page 24

April 2010 – March 2011

Shire Pharmaceutical Development, Inc A Phase 3, Double-Blind, Placebo-Controlled, Principal Investigator Multicentre,Randomised-Withdrawal, Long-Term Maintenance of Efficacy and Safety Study of Extended- Release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 with Attention- Deficit/Hyperactivity Disorder April 2010 – August 2013

Eli Lilly and Company A Double-Blind, Efficacy and Safety Study of Principal Investigator versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder April 2010 – December 2011

Shire Pharmaceutical Development, Inc A Phase 4, Randomized, Double-Blind Multi-Center, Principal Investigator Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of SPD489 on Executive Function (Self-regulation) Behaviors in Adults with Attention- Deficit/Hyperactivity Disorder (ADHD) Reporting Clinically Significant Impairment of Real-World Executive Function Behavior May 2010 – February 2011

Otsuka Pharmaceutical Development & A Phase 2, Multicenter, Randomized, Double-Blind, Commercialization, Inc. Placebo-Controlled Study of the Safety and Efficacy of Principal Investigator OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder July 2010 – September 2011

Pharmaceutical Research (cont.):

Shire Pharmaceutical Development, Inc Consortium for the Lifespan Examination of ADHD Principal Investigator Registry (CLEAR) Study: A Phase 4, International, Longitudinal, Observational Study of Individuals with Attention-Deficit/Hyperactivity Disorder (ADHD) October 2010 – October 2011

Novartis Pharmaceuticals Corp A 40-Week, Randomized, Double-Blind, Placebo- Principal Investigator Controlled, Multicenter Efficacy and Safety Study of Ritalin LA in the Treatment of Adult Patients with Childhood-Onset ADHD Page 25

October 2010 – May 2012

Shire Pharmaceutical Development, Inc A Phase 3b, Double-Blind, Randomised, Active- Principal Investigator Controlled, Parallel-Group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy. October 2010 – October 2012

Bristol-Meyers Research and Development Safety and Efficacy of Aripiprazole in the Long-Term Principal Investigator Maintenance Treatment of Pediatric Patients with Irritability Associated with Autistic Disorder January 2011 – June 2012

Novartis Pharmaceuticals Corp A 6-Month, Open-Label Extension to a 40-Week, Principal Investigator Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Ritalin® LA in the Treatment of Adult Patients with Childhood-Onset ADHD March 2011 – May 2012

Otsuka Pharmaceutical Development & A Phase 2, Multicenter, Open-Label Study to Assess the Commercialization, Inc. Safety and Tolerability of Oral OPC-34712 as Adjunctive Principal Investigator Therapy in Adult Patients with Major Depressive Disorder March 2011 – February 2013

Pharmaceutical Research (cont.):

Otsuka Maryland Research Institute, Inc. A Long-Term, Multicenter, Randomized, 31-09-266 Double-Blind, Placebo-Controlled Study to Evaluate the Principal Investigator Efficacy, Safety, and Tolerability of Aripiprazole (OPC- 14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia June 2011 – June 2013

Shionogi, Inc. A 40-Week, Phase 4, Double-Blind, Placebo- Principal Investigator Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY (clonidine hydrochloride) Extended-Release in Children and Adolescents with Attention-Deficit/ Hyperactivity Disorder Page 26

August 2011 – January 2013

Otsuka Pharmaceutical Development & A Phase 3, Multicenter, Randomized, Double-Blind, Commercialization, Inc. Placebo-Controlled Trial of the Safety and Efficacy of Principal Investigator Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Polaris Trial August 2011 – August 2012

Shire Pharmaceutical Development, Inc A Phase 3, Double-Blind, Randomized, Multi- Principal Investigator Center, Placebo-Controlled, Dose-Optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once-Daily Dosing with Extended-Release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) September 2011 – July 2013

Novartis Pharmaceuticals Corp A Multicenter, Open-Label, Sequential-Cohort, Principal Investigator Dose-Escalation, 14-Day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone (Fanapt®) 12 to 24 mg/day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/day) in Adolescent Patients (Aged 12 to 17 Years) September 2011 – March 2013

Pharmaceutical Research (cont.):

Shire Development, Inc. A Phase 2, Randomized, Double-Blind, Placebo- Principal Investigator Controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years with Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) December 2011 – September 2013

Pfizer, Inc. A Multicenter, Randomized, Double-Blind, Principal Investigator Placebo-Controlled, Fluoxetine-Referenced, Parallel- Group Study to Evaluate the Efficacy, Safety and Tolerability of Succinate Sustained Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder December 2011 – August 2015

Page 27

Pfizer, Inc. A 6-Month, Open-Label, Multi-Center, Principal Investigator Flexible Dose Extension Study to the B2061014 Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder December 2011 – January 2015

Otsuka Pharmaceutical Development & A Long-Term, Phase 3, Multicenter, Open-Label Trial to Commercialization, Inc. Evaluate the Safety and Tolerability of Oral OPC-34712 Principal Investigator as Adjunctive Therapy in Adults with Major Depressive Disorder, the Orion Trial February 2012 – January 2014

Otsuka Maryland Research Institute, Inc. A Long-Term, Multicenter, Randomized, 331-10-227 Double-Blind, Placebo-Controlled Study to Principal Investigator Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia February 2012 – January 2014

Shire Development Inc. A Phase 4, Randomized, Double-Blind, Principal Investigator Multicenter, Parallel-Group, Active-Controlled, Dose- Optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention- Deficit/Hyperactivity Disorder (ADHD) April 2012 – March 2014

Pharmaceutical Research (cont.):

Shire Development Inc. A Phase 4, Randomized, Double-Blind, Principal Investigator Multicenter, Parallel-Group, Active-Controlled, Forced- Dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®)with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention- Deficit/Hyperactivity Disorder (ADHD) April 2012 – July 2014

Janssen Research & Development, LLC A Randomized, Multicenter, Double-Blind, Principal Investigator Non-Inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia April 2012 – August 2014

Page 28

Sunovion Pharmaceuticals Inc. A Double-Blind, Placebo-Controlled, Principal Investigator Randomized Withdrawal Study of Lurasidone for the Maintenance Treatment of Subjects with Schizophrenia April 2012 – December 2013

Sunovion Pharmaceuticals Inc. A 12-Week, Multicenter, Open-Label Principal Investigator Extension Study in Subjects with Schizophrenia April 2012 – December 2013

NextWave Pharmaceuticals, Inc. A Multicenter, Dose-Optimized, Double- Principal Investigator Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of NWP09 in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom June 2012 – December 2012

Forest Research, Inc. An Open-Label Study of the Safety and Tolerability of Principal Investigator in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) August 2012 – September 2013

Forest Research, Inc. An Open-Label Extension Study of the Principal Investigator Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) August 2012 – March 2014

Pharmaceutical Research (cont.):

Forest Research, Inc. A Double-Blind, Placebo-Controlled, Principal Investigator Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine August 2012 – October 2013

Shire Development, Inc. Qualitative Assessment of the Functional Principal Investigator Status of Children with Attention-Deficit/ Hyperactivity Disorder (ADHD) August 2012 – May 2013

Shire Development, Inc. A Qualitative Study for Concept Page 29

Principal Investigator Elicitation about Adolescents’ Experiences with Attention-Deficit/Hyperactivity Disorder (ADHD) and Pharmacological Treatments August 2012 – May 2013

Shire Development LLC The SPD489-343, Phase 3, Multicenter, Randomized, Principal Investigator Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18- 55 Years with Moderate to Severe October 2012 – November 2013

Noven Pharmaceuticals, Inc. A Randomized, Double-Blind, Placebo- Principal Investigator Controlled, Cross-Over, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents with ADHD December 2012 – July 2013

Theravance, Inc. A Phase 2 Multicenter, Randomized, Principal Investigator Double-Blind, Parallel, Placebo-Controlled Proof-of- Concept Study of TD-9855 in Adults with Attention- Deficit/Hyperactivity Disorder (ADHD) January 2013 – November 2013

Shire Development LLC A Phase 3, Multicenter, Open-label, 12-Month Extension Principal Investigator Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder February 2013 – December 2014

Pharmaceutical Research (cont.):

Noven Pharmaceuticals, Inc. An Investigational Study to Evaluate the Principal Investigator Usability of d-Amphetamine Transdermal System (d- ATS) in Children, Adolescents and Adults with ADHD April 2013 – August 2013

Arbor Pharmaceuticals A Randomized, Double‐Blind, Placebo‐ Principal Investigator Controlled, Forced Titration, Proof‐of‐Concept Study of AR08 in the Treatment of Attention-Deficit/ Hyperactivity Disorder in Children (Ages 6‐17) May 2013 – December 2014

Neos Theapeutics A Randomized, Multicenter, Double-Blind, Principal Investigator Placebo-Controlled, Parallel Group Study of NT0102 Methylphenidate Polistirex Extended-Release Oral Disintegrating Tablets (Equivalent to 20, 30, 40, or 60 Page 30

mg of Methylphenidate Hydrochloride) in Children (Ages 6-12 Years) with Attention-Deficit/Hyperactivity Disorder June 2013 – July 2014

Ironshore Pharmaceuticals A Phase I/II, Single Center, Single-Treatment, Open- Development, Inc. Label, Adaptive Clinical Trial Design Examining the Principal Investigator Pharmacokinetic Effects of up to Two Separate HLD200 Modified-Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects with Attention- Deficit/ Hyperactivity Disorder August 2013 – March 2014

Sunovion Pharmaceuticals 6-Week Randomized, Parallel, Double- Principal Investigator Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects with Irritability Associated with Autistic Disorder August 2013 – January 2015

H. Lundbeck A/S An Open-Label Study Evaluating the Principal Investigator Pharmacokinetics and Tolerability of Lu AA21004 in Connection with Multiple Oral Dosing of Lu AA21004 in Child and Adolescent Patients with a DSM-IV-TR Diagnosis of Depressive or Anxiety Disorder September 2013 – December 2014

Pharmaceutical Research (cont.):

Forest Research Institute, Inc. A Double-Blind, Placebo-Controlled Principal Investigator Evaluation of the Safety and Efficacy of in Adolescent Patients with Major Depressive Disorder September 2013 – June 2016

XXXXXX A 104-Week, Flexible-Dose, Open-Label, Principal Investigator Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of XXXXXX in Pediatric Subjects with Schizophrenia and Subjects with Irritability Associated with Autistic Disorder October 2013 – Present

Neurovance, Inc., Pharmaceuticals An Exploratory, Single-Blind Pilot Study of Principal Investigator Flexible Doses of the Triple Inhibitor EB-1020 SR in the Treatment of Adult Males with Attention- Deficit/Hyperactivity Disorder Page 31

October 2013 – March 2014

Arbor Pharmaceuticals A Multicenter, Dose-Optimized, Double- Principal Investigator Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) with Attention- Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom November 2013 – June 2014

Tris Pharma Amphetamine Extended-Release Oral Principal Investigator Suspension in the Treatment of Children with ADHD: A Laboratory School Study February 2014 – October 2014

Alcobra Ltd. A 6-Week Randomized, Multicenter, Principal Investigator Double-Blind, Parallel, Fixed-Dose Study of MG01CI (Metadoxine Immediate-Release/Slow-Release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) March 2014 – October 2014

Ironshore Pharmaceuticals & A Phase III Clinical Endpoint Evaluation Development, Inc. Study Examining the Safety and Efficacy of Principal Investigator HLD200 in Pediatric Subjects with Attention-Deficit/ Hyperactivity Disorder April 2014 – November 2014

Pharmaceutical Research (cont.):

Purdue Pharma A Phase III, Randomized, Double-Blind, Principal Investigator Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients April 2014 – August 2015

Purdue Pharma A Phase III, Randomized, Double-Blind, Principal Investigator Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients April 2014 – August 2015

Purdue Pharma A Six-Month, Open-Label, Multi-Center Principal Investigator Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents with ADHD April 2014 – August 2015

Page 32

Shire Development LLC Qualitative Interviews with Adult Patients Principal Investigator Diagnosed with Attention-Deficit/Hyperactivity Disorder May 2014 – April 2015

Sunovion Pharmaceuticals A Phase 3, 12-Month, Multicenter, Open- Principal Investigator Label, Flexibly-Dosed, Safety Study of SEP-225289 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) July 2014 – July 2016

Purdue Pharma A Randomized, Double-Blind Study of the Principal Investigator Time Course of Response of PRC-063 in Adults with ADHD in a Simulated Adult Workplace Environment August 2014 – August 2015

Noven Pharmaceuticals, Inc. An Investigational Study to Evaluate the Usability of Principal Investigator D-Amphetamine Transdermal System (D-Ats) in a Naturalistic Setting and to Assess Adhesion of d-ATS Compared to Daytrana® in the Clinic Setting in Children, Adolescents and Adults with ADHD September 2014 – March 2015

Tris Pharma Evaluation of the Single Dose Pharmacokinetics of Principal Investigator TRI102 in Children with ADHD February 2015 – April 2015

Pharmaceutical Research (cont.):

Shire Development LLC A Phase 2, Open-Label, Multicenter, Exploratory Safety, Principal Investigator Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-Deficit/Hyperactivity Disorder April 2015 – August 2016

Noven Pharmaceuticals, Inc. An Investigational Study to Evaluate the Usability of Principal Investigator Methylphenidate Transdermal System (MTS) in a Naturalistic Setting and to Asses Adhesion of MTS and Daytrana ® in the Clinic Setting in Children, Adolescents and Adults with ADHD April 2015 – September 2015

Sunovion Pharmaceuticals A 6-Week, Randomized, Double-Blind, Multicenter, Principal Investigator Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Page 33

Years of Age with Attention-Deficit/ Hyperactivity Disorder (ADHD) April 2015 – October 2016

Shire Development LLC A Phase 3, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years with Attention-Deficit/ Hyperactivity Disorder (ADHD) June 2015 – April 2016

XXXXXX A Phase 3, Open-Label, Multicenter, 12-Month Safety Principal Investigator and Tolerability Study of XXXXX in Preschool Children Aged 4-5 Years Diagnosed with Attention- Deficit/Hyperactivity Disorder July 2015 – Present

Sunovion Pharmaceuticals An Open-Label, Flexibly-Dosed, 26-Week Extension Principal Investigator Safety Study of Dastroline in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) July 2015 – April 2017

Neurovance, Inc. A Phase IIb, Randomized, Double-Blind, Multicenter, Principal Investigator Placebo Controlled, Crossover, Safety and Efficacy Study of Sustained-Release (CTN SR) in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) July 2015 – March 2016

Pharmaceutical Research (cont.):

XXXXXX A Phase 3, Randomized, Double-Blind, Multicenter, Principal Investigator Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of XXXXX in Adults Aged 18-55 Years with Attention-Deficit/Hyperactivity Disorder (ADHD) October 2015 – Present

Shire Development LLC A Phase 1, Open-Label Study of the Pharmacokinetics of Principal Investigator d- and l-Amphetamine after a Single Dose of SHP465 12.5 mg or 25 mg Administered to Children and Adolescents Aged 6 to17 Years with Attention-Deficit/ Hyperactivity Disorder (ADHD) October 2015 – February 2016

Ironshore Pharmaceuticals A Phase 3, Multicenter, Open-Label Treatment- & Development, Inc. Optimized, Double-Blind, Randomized, Placebo- Page 34

Principal Investigator Controlled, Forced-Withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 with Attention- Defici/ Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting September 2015-March 2016

Shire A Phase 3, Randomized, Double-Blind, Multi-Center, Principal Investigator Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years with Attention-Deficit/ Hyperactivity Disorder (ADHD) November 2015 – July 2016

H. Lundbeck A/S Interventional, Randomised, Double-Blind, Placebo- Principal Investigator Controlled, Fixed-Dose Study of in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) November 2015 – November 2016

Medgenics, Inc. A Noninterventional Genotype/Phenotype Study of Principal Investigator mGluR Mutations in Children and Adolescents with Attention-Deficit/ Hyperactivity Disorder (ADHD) January 2016 – April 2017

Pearson Reference Database Development for the Principal Investigator Quotient® iPad Test (Ages 6 - 80 Years Old) February 2016 – June 2017

Pharmaceutical Research (cont.):

Sunovion Pharmaceuticals A Randomized, Multicenter, Double-Blind, Principal Investigator Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Dastroline in Children Aged 6 to 12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting April 2016 – March 2017

XXXXXX A Randomized, Double-Blind, Placebo-Controlled, Principal Investigator Flexible-Dose Titration Study of XXXXXX in Children Ages 4 to Under 6 Years Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) April 2016 – Present

XXXXXX A 12-Month Open Label Safety Study of Principal Investigator XXXXXX in Children Ages 4-5 Years Diagnosed with Attention-Deficit/ Hyperactivity Disorder Page 35

(ADHD) April 2016 – Present

XXXXXX A Randomized, Controlled, Parallel-group, Principal Investigator Intervention Study to XXXXXX in Improving Attention in Pediatric Subjects Ages 8 to 12 Years Old with Attention-Deficit/Hyperactivity Disorder (ADHD) May 2016 – Present

Medgenics, Inc. ,Principal Investigator A Multicenter, 6-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Design Study to Assess the Efficacy and Safety of NFC- 1 in Adolescents (Ages 12-17 Years) with Genetic Disorders Impacting Metabotropic Glutamate Receptors and Attention-Deficit/Hyperactivity Disorder June 2016 – March 2017

XXXXXX A Pharmacokinetic/Pharmacodynamic Study of Principal Investigator XXXXXX in Pediatric Attention-Deficit/ Hyperactivity Disorder (ADHD) Patients in a Laboratory Classroom July 2016 – Present

Pharmaceutical Research (cont.):

NLS-1 Pharma AG A Phase II Study to Determine the Efficacy, Safety, Principal Investigator Tolerability, and Pharmacokinetics of a Controlled Release (CR) Formulation of in Adults with DSM-5 Attention-Defici/ Hyperactivity Disorder (ADHD) September 2016 – January 2017

Ironshore Pharmaceuticals A Phase II, Single-Center, Open-Label, Dose- & Development, Inc Titration Study Designed to Examine the Safety, Principal Investigator Tolerability, and Efficacy of Evening Dosed HLD100, a Novel Delayed and Extended Release (DR/ER) Formulation of Sulfate, in Children with Attention-Deficit/ Hyperactivity Disorder September 2016 – March 2017

Page 36

XXXXXX An Exploratory Study to Assess the Sustained Principal Investigator Effects of XXXXXX in Pediatric Subjects Ages 8 to 12 Years Old with Attention-Deficit/ Hyperactivity Disorder (ADHD) September 2016 – Present

Medgenics, Inc. An Open-Label, Single Ascending Dose, Principal Investigator Pharmacokinetic and Tolerability Study of NFC- 1 in Children and Adolescents (Ages 6-17 Years) with Attention-Deficit/Hyperactivity Disorder December 2016 – April 2017

XXXXXX A Phase 3, Randomized, Double-Blind, Multicenter, Principal Investigator Parallel-Group, Placebo-Controlled, Dose-Optimization Safety and Efficacy Study of XXXXXX in Preschool Children Aged 4-5 Years with Attention- Deficit/Hyperactivity Disorder --- 2017 – Present

Tris Pharma Dyanavel® XR Extended-Release Oral Suspension Principal Investigator in the Treatment of Children with ADHD: A Laboratory School Study. February 2017- April 2017

Page 37

Pharmaceutical Research (cont.):

Purdue A Phase 3, Randomized, Double-Blind, Principal Investigator Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) with ADHD April 2017- November 2017

XXXXXX A Multicenter, 3-Part, 6-Week, Double-Blind, Principal Investigator Randomized, Placebo-Controlled, Parallel-Design Study to Assess the Efficacy and Safety of XXXXX in Children and Adolescents (Ages 6-17 Years) with Attention-Deficit/Hyperactivity Disorder and with or without Copy Number Variants in XXXXXX Signaling and Neuronal Activity August 2017- Present

XXXXXX A Non-Interventional Study to Identify Children Principal Investigator and Adolescents (Ages 6-17 Years) with Attention- Deficit/Hyperactivity Disorder and with or without Copy Number Variants in XXXXXX Signaling and Neuronal Connectivity November 2017- Present

XXXXXX Protocol name: A Multicenter, Dose-Optimized, Principal Investigator Double-Blind, Randomized, Placebo-Controlled, XXXXXX Laboratory Classroom Study with XXXXXX in Children with Attention-Deficit/ Hyperactivity Disorder November 2017- Present

XXXXXX A Multicenter, Dose-Optimized, Open-Label Safety Principal Investigator Study with XXXXXX in Children with Attention- Deficit/Hyperactivity Disorder (ADHD). November 2017- Present

XXXXXX A Phase 4, Double-Blind,Rrandomized, Principal Investigator Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of XXXXXX in 4- 5 Year Old Children with Attention- Deficit/ Hyperactivity Disorder (ADHD). --- 2017 – Present

Page 38

Pharmaceutical Research (cont.):

XXXXXX A Phase 4, 6-Month Open-Label Extension Study to Principal Investigator Evaluate the Safety, Tolerability and Efficacy of XXXXXX in Children with Attention-Deficit/ Hyperactivity Disorder (ADHD) --- 2017 – Present

XXXXXX A Phase 2, Multicenter, Randomized, Double- Principal Investigator Blind, Active- and Placebo-Controlled Trial of the Safety and Efficacy of XXXXXX in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD). October 2017-Present